DOCSLIB.ORG

Author Index

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Author Index Author Index The numbers shown in square brackets are the numbers of the references in the bibliography. Page numbers in italiC<J refer to the bibliography" Abajian, J., Jr., Brazell, E. Ahlgren, I., Aronsen, K. F. Allaria, R, Galligari, G., H., Dente, G. A., Mills, 181,228 Bottani, G., Castelli, S. E. L. 306, 320 -- Ericsson, B., Fajgelj, 174, 176, 202, 203, 228 - see Mazuzan, J. E. 169, A. 181,228 Allen, C. R., see Walker, J. 171,235 - see Belfrage, S. 58, 66 A. 166, 172, 175, 177, - see Shinozaki, T. 36,51, Ahlgren, L., see Belfrage, S. 201, 204, 206, 207, 240 75, 169, 172, 175, 176, 512,526 - see Wilson, R. D. 112, 177,238 Ahlmark, A., Forssman, S. 122 Abbott 77 350,354 Allen, G. D., Ward, R. J., Abbott, B. C., Mommaerts, Aikawa, J. K., see Virtue, Perrin, E. R 46, 66 W. F. H. M. 228 R. W. 247,253 - see Ward, R. J. 240 Abboud, F. M., see Caffrey, Akester, J. M., Brody, M. J. Allen, J. G., see Adams, W. J. A. 53,67,184,230 183,228 F. 492,499 Abel, F. L., Waldhausen, J. Albers, C., Brendel, W., Allison, A. C., Nunn, J. F. A. 118 Usinger, W. 281,284 63,66 - see Sutherland, A. 160, Albert, S. N., Jain, R. C., Allweis, C., Magnes, J. 239 Shadid, .J. N. 200, 228 394,395,404 Abere, J. F., see Bovey, F. Albin, M. S., Horrocks, L. - see Barkai, A. 395, 404 20, 30 A., Kretchmer, E. 12,.30 Allweis, C. L., see Gainer, H. Abernathy, R. S., see Te­ Aldinger, E. E., see Mahaf­ 395,405 schan, P. E. 250,253 fey, J. E. 167, 170 Alper, M. H., Flacke, W. Abiko, Y., Ito, G. 125,127, 235 187,228 141 - see Thrower, W. B. - Fleisch, J. H., Flacke, W. -- Higuchi, 1., Kaneko, 187,240 134,137,141 Y., Ishikawa, H., Ito, M. Aldrete,.J. A., Virtue, R. W. - Gillis, R. A., Flacke, W. 141 431,436 179,228 Abrahamson, E. A., see Aldridge. W. N., Parker, V. - see Flacke, W. 50, 69, Arky, R. A. [6~j 523,527 H. 393,404 138, 143, 176, 179, 187, Abrams, A. L., see Grable, Alexander, H., see Cohen, P. 199, 232 E. 55,70,200,233 J. 390, 391, 395, 396, - see Fletcher, S. W. 69, Abreu, B. E., see Gardier, 404 138,139,143 R. W. 126,143 Alexander, M., see Artusio, - see Garfield, J. M. 42, Adam, A., see Ausherman, J. F. Jr. 91. 211, 229, 50, 54, 69. 134, 137, 139, H. M. 190, 229 306, 311, 320, 424, 433, 144.232 Adams, J. G., Jr., see Pat­ 436 -seeGillis,R.A. 137,144 terson, J. F. 28,31 Alexander, S., James, F. M., - see Rutledge, C. O. 74 Adams, W. F., Thornton, T. Colton, E. T., Gleaton, Alpert, S., Coakley, C. S. F., Allen, J. G., Gonzales, H. R., Wollman, H. 55,68 D. E. 492, 499 391,404 Alstatt, A. H., see McAle­ Adamson, D. W., Green, A. Alexander, R. C., Cohen, P. avy, J. C. 42, 72 F. 475 J., Wollman, H., Smith, Alter H., see Rehder, K. Adamson, J. S., Jr., see T. C., Reivich, M., Mole 41, 74, 348, 355, [43] Schultz, J. C. [48]517,526 R. A. U. 279, 284 515,526 Adrian, E. D., Matthews, R. - Wollman, H., Cohen, P. - see Stier, A. 348, 355 366,38,) J., Chase, P. E., Behar, Altura, B. M., see Hershey, Adriani, J. 492, 500 M. 182,228 S. G. 65,70 - Yarberry, O. H., .Jr. - see Behar, M. G. 55,66, Andersen, E. W., see Ander­ 463,475 201,229 sen, N. 228 Adson, M. A., see Dawson, - see Cohen, P. J. 46,61, Andersen, H. A., see Code, B. 526 62,68,281,282,284 C. F. 300,321 Aguilar, V., see Barkulis, S. - see Wollman, H. 44,61, Andersen, K., Ringsted, A. S. 400,404 76,182,240,281,287 318,320 Author Index 529 Andersen, N. 319, 320 Armitage, A. K. 127, 142 Babad, A. A. see Munson, E. - Andersen, E. W. 228 Aronsen, K. F., see Ahlgren, S. 45,73. 98, 102, 257, - Johansen, S. 194, 200, 1. 181,228 269 228 Aronson, H. B., Laasberg, - see Saidman, L. J. 36, Andersen, N. B. 62, 66, L. H., Charm, S., Etsten, 41,74,256,270 247,251,272,284 B. E. 55, 66, 201, 214, Babior, B. M., Davidson, C. AnderB!lll1 T, W' 1 Bee Gra­ !?:?~ S. L26J 512, 526 venstein, J. S. 132,139, - Levesque, P. R., Charm, - Trey, C. [54] 518, 526 144 S., Etsten, B. E. 229 Bachelard, H. S. 395, Anderson, E. G., see Bonny­ Artusio, J. F., Jr. 29, 30, 404 castle, D. D. 403, 404 91, 107, 112, 118, 306, - Gaitonde, M. K., Vrba, Anderson, J. J., Bolt, R. J., 320 R. 395,404 Ullman, B. M., Bass, P. - Hunt, R. E., Tiers, F. M., Bachman, L. 179, 229, 320 Alexander, M. 91, 433 245,252 Anderson, J. P., see Rossen, - van Poznak, A. 63, 66, - see Richards, C. C. 211, R. 387,407 91, 423, 424, 425, 436 237 Andrew, D., see Mc Clish, A. -- Beirne, J. H., Merin, Backman, L. E., LOfstrom, 197,235 R. G. 89,91 B., Widen, L. 43, 66, Andrews, 1. C., Orkin, L. R. -- Hunt, R. E., Tiers, F. 108,114,115,118 259,268 M., Alexander, M. 211, Baekeland, F., Greene, N. - Zauder, H. L., Orkin, L. 229, 306, 311, 320, 424, M. 489,500 R. 169,204,228 436 Baez, S., Orkin, L. R. 54, - see Marx, G. F. 45, 72 -- Weingram, J. 90 66,184,208,229 Anfinsen, C. B., see Beecher, --- Sohn, Y. J. 139, - Zauder, H. L., Orkin, L. H. K. 276, 284 142,218,229 R. 229 Anichkov, S. V., Belenkii, - see Hunt, R. E. 85, 91 - see Kadis, L. B. 189, M. L. 125, 141 - see van Poznak, A. 92, 199, 234 Anisimova, A. N., see Eng­ 424,433,438 - see Zauder, H. L. 208, lin, M. A. 425, 437 Asatoor, A. M., Levi, A. J., 216,226,241 Ankeney, J. L., see Boett­ Milne, M. D. 498, 500 Bagad, A. A., see Saidman, ner, R. B. 180, 230 Asher, M., Frederickson, E. L. J. 106,112,113,114, Annamunthodo, H., Kea­ L. 174, 185, 229 117,122 ting, V., Patrick, S. J. Askrog, V. F. 255,268 Bagwell, E. E. 179, 229 281,284 - Pender, J. W., Smith, T. - Durst, G. G. 139, 142 - see Keating, V. 62, 71, C., Eckenhoff, J. E. 66, -- Linker, R. P. 138, 281,286 255,268 139, 142 Anon 5,17,18,30 Atanackovic, D., Dalgaard- - Gadsden, R. H., Risin­ Ansell, G. B., Dohmen, H. Mikkelsen, S. 125, 142 ger, K. B. H., Woods, 400,404 Atkinson, M. 302, 320 E. F. 97,101,215,216, - Morgan, A. 401, 404 Atkinson, R. S. 116, 118 229 Anton, A. H., Gravenstein, - see Lee, J. A. 306, 323 - Woods, E. F. 91,95,96, J. S., Wheat, M. W., Jr. Ausherman, H. M., Adam 101, 137, 14.'2, 201, 202, 198,228 A. 190,229 205,206,209,229 Aoba, Y., see Inagaki, M. Austen, "\V., see Lowenstein, -- Gadsden, R. H. 91, 95,101,433 E. 464,477 202,209,229 Apivar, D. 225,228 Austen, W. G., see Rein, J. -- Mahaffey, J. E. 91 Appel, K. E., see Kety, S. S. 74, 138, 147, 170, 174, Bahga, H. S., Link, R. P. 388,389,406 176, 200, 237 470,475 Aprahamian, H. A., Van­ Austin, A. T. 483, 486, 487 Baker, L. W., Jones, P. F., derveen, J. L., Bunker, Austin, G. M., Pask, E. A. Dudley, H. A. F. 318, J. P., Murphy, A. J., 113,118 320 Crawford, J. D. 244, Aviado, D. M., see Klide, - Webster,D.R. 318, 251,279,284 A. M. 47, 71, 139, 145 320 Arens, J. F. 213, 228 Awalt, C. H., Frederickson, Balagot, R. C., see Sadove, Ariens, E. J. 488,500 E. L. 187,229 M. S. 93, 95, 98, 99, - van Rossum, J. M., Si­ Axelrod, J. 352, 354 102,216,217,238 monis, A. M. 488, 493, - see Whitby, L. G. 137, - see Tsuji, H. 400, 408 500 148 Baldwin, M., see Galindo, Arimura, A., see Oyama, T. Axelson, S., see Belfrage, S. A. H. 170, 174, 181, 277,286,292,297 58, 66, [37] 512, 526 232 Arko, H., see Kivalo, E. Ayre, P. 449, 450, 475 Ball, E. G., Cooper, O. 401, 131,145 404 Arky, R. A., Ververbrante, Ball, M. R., see Hammond, E., Abrahamson, E. A. Babad, A. A. 169,229 W. G. 277, 286, 292, [63] 523, 527 - Eger, E. 1., II. 42, 66 297 34 Handbook of expo Pharmacology, Vol. XXX 530 Author Index Bamforth, B. J., Siebecker, Bartelstone, H. J., Katz, R. Beecher, H.K., McDonough, K. L, Kraemer, R., L., Ngai, S. H. 129,142 F. K. 108, 118 Orth, O. S. 82, 91, 212, - Nasmyth, P. A. 131, -- Forbes, A. 114, 118 229 142 - see Brewster, W. R., Jr. -- Steinhaus, J. E., Orth, - see Epstein, R. A. 49, 276,277,284 S. O. 171,175,229 69,119,139,143 - see Bunker, J. P. 276, - see Siebecker, K. L. 92 - see Wang, H. H. 49,75 284 Banerji, H., Reid, C. 276, Bartolini, A., Pepeu, G. - see Burnett, C. H. 242, 284 402,404 249,252 Banks, A. A., Campbell, A., Bartot, G., see Cessi, C. 46, - see Cohen, E. N.
Load more

Recommended publications
  • Veterinary Anaesthesia (Tenth Edition)
    W. B. Saunders An imprint of Harcourt Publishers Limited © Harcourt Publishers Limited 2001 is a registered trademark of Harcourt Publishers Limited The right of L.W. Hall, K.W. Clarke and C.M. Trim to be identified as the authors of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without either the prior permission of the publishers (Harcourt Publishers Limited, Harcourt Place, 32 Jamestown Road, London NW1 7BY), or a licence permitting restricted copying in the United Kingdom issued by the Copyright Licensing Agency Limited, 90 Tottenham Court Road, London W1P 0LP. First edition published in 1941 by J.G. Wright Second edition 1947 (J.G. Wright) Third edition 1948 (J.G. Wright) Fourth edition 1957 (J.G. Wright) Fifth edition 1961 (J.G. Wright and L.W. Hall) Sixth edition 1966 (L.W. Hall) Seventh edition 1971 (L.W. Hall), reprinted 1974 and 1976 Eighth edition 1983 (L.W. Hall and K.W. Clarke), reprinted 1985 and 1989 Ninth edition 1991 (L.W. Hall and K.W. Clarke) ISBN 0 7020 2035 4 Cataloguing in Publication Data: Catalogue records for this book are available from the British Library and the US Library of Congress. Note: Medical knowledge is constantly changing. As new information becomes available, changes in treatment, procedures, equipment and the use of drugs become necessary. The authors and the publishers have taken care to ensure that the information given in this text is accurate and up to date.
    [Show full text]
  • Un Novedoso Enfoque Para El Diseño De Fármacos Antimicrobianos Asistido Por Computadora
    TOMOCOMD-CARDD: Un Novedoso Enfoque para el Diseño de Fármacos Antimicrobianos Asistido por Computadora Autora: Yasnay Valdés Rodríguez. Tutores: Prof. Dr. Yovani Marrero Ponce. Prof. MSc. Ricardo Medina Marrero. 2005-2006 La ignorancia afirma o niega rotundamente; la ciencia duda… Voltaire (1694-1778) Quiero dedicar este trabajo a todas aquellas personas que me aprecian y desean lo mejor para mi, especialmente a mis padres. A mi padre Dedico este trabajo con mucho amor, por hacerme comprender que siempre se puede llegar mas lejos, y que no hay nada imposible, solamente hay que luchar... A mi madre Por su infinita bondad, por su sacrificio inigualable. A mis familiares Por todo su apoyo y ayuda que me han mostrado incondicionalmente. A mi hermano Por ser mi fuente de inspiración. A la humanidad “...porque si supiera que el mundo se acaba mañana, yo, hoy todavía, plantaría un árbol” Quiero agradecer a todas aquellas personas que me han ayudado a realizar este sueño: A mis padres por todo el sacrificio realizado, y aún parecerles poco, los amo mucho. A mi madre por estar siempre a mi lado en los buenos y malos momentos ayudándome a levantarme en cualquier recaída. A mi padre por guiarme en la vida y brindarme sus consejos siempre útiles, por darme fuerza y vitalidad. A mi mayor tesoro, mi hermano, que me alumbra de esperanza día a día. A mis tías y primos que me ayudaron mucho, aún estando lejos. A mi novio que me apoyo en todas mis decisiones y con paciencia supo ayudarme. A mis tutores y cotutores que siempre me dieron la mano; especialmente a Yovani por su paciencia, a quien debo gran parte de mi formación como profesional por sus exigencias.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Xerox University Microfilms
    INFORMATION TO USERS This material was produced from a microfilm copy of the original document. While the most advanced technological means to photograph and reproduce this document have been used, the quality is heavily dependent upon the quality of the original submitted. The following explanation of techniques is provided to help you understand markings or patterns which may appear on this reproduction. 1.The sign or "target" for pages apparently lacking from the document photographed is "Missing Page(s)". If it was possible to obtain the missing page(s) or section, they are spliced into the film along with adjacent pages. This may have necessitated cutting thru an image and duplicating adjacent pages to insure you complete continuity. 2. When an image on the film is obliterated with a large round black mark, it is an indication that the photographer suspected that the copy may have moved during exposure and thus cause a blurred image. You will find a good image of the page in the adjacent frame. 3. When a map, drawing or chart, etc., was part of the material being photographed the photographer followed a definite method in "sectioning" the material. It is customary to begin photoing at the upper left hand corner of a large sheet and to continue photoing from left to right in equal sections with a small overlap. If necessary, sectioning is continued again — beginning below the first row and continuing on until complete. 4. The majority of users indicate that the textual content is of greatest value, however, a somewhat higher quality reproduction could be made from "photographs" if essential to the understanding of the dissertation.
    [Show full text]
  • Environmentally Acceptable Flame Extinguishants
    ENVIRONMENTALLY ACCEPTABLE FLAME EXTINGUISHANTS J. Douglas Mather, Ph. D. Robert E. Tapscott, Ph.D., Chemical Development Studies, Inc. GlobeTech, Inc. 7636 William Moyers Ave. NE 8200 Montgomery Blvd. NE, #218 Albuquerque, NM 87122 Albuquerque, NM 87109 505-797-9706 505-883-9399 [email protected] [email protected] INTRODUCTION Research geared to the identification and testing of environmentally friendly extinguishants – specifically compounds with low boiling points suitable for use in cold environments - is sponsored by the National Institute of Standards and Technology and the Next Generation Fire Suppression Technology Program. Low temperature conditions are a characteristic of aircraft in-flight at higher altitudes. Fire suppression agents with lower boiling points are expected to disperse more rapidly and uniformly than higher boiling agents. A broad review of chemical families identified many with potential to meet the restrictive list of requirements for a suitable halon replacement. This subsequent chemical selection effort builds on several prior projects and guidance from in depth assessment of a wide range of chemical families [1, 2., 3, 4, 5, 6] Chemical families examined as potential sources of halon 1301 alternatives covered a broad range of elements, chemical functionalities. Information relating to environmental persistence, toxicity, flame suppression, reactivity and a number of other factors were considered. The resulting list of chemical families presented as being worthy of continued or initial consideration ranged from brominated carbon based compounds to metal containing compounds. The current focus on low boiling compounds eliminated many of theses down-selected chemical families. The remaining chemical families were reexamined and the higher boiling members eliminated from further consideration.
    [Show full text]
  • Central Nervous Systems’ Effects of Isoflurane
    CENTRAL NERVOUS SYSTEMS' EFFECTS OF ISOFLURANE (FORANE) EVA M. KAVAN, M.D. AND ROBERT M. JULIEN, PH.D. INTRODUCTION [SOFLUBANE (Forane,* 1-chloro-2,2,2,-trifluoroethyl difluoromethyl ether (is a re- cently developed short-chain halogenated inhalation agent. It is an isomer of enflu- rane, with a different boiling point and vapour pressure? Isoflurane provides rapid induction as well as prompt emergence from anaesthesia. Isoflurane-induced an- aesthesia has been investigated in experimental animals 2-4 and in man. ~-8 Its effects on the cortical EEG have been determined in dogs, 4 in human volunteers 7 and in patients during operations. 8 However, the effects of isoflurane on subcortical struc- tures have not been investigated. The present study was conducted to supply these data. METHODS A. Chronic Experiments Five cats (average weight 4.8 kg) were used in eight experiments. Under pento- barbital anaesthesia, using sterile technique, bipolar concentric stainless steel elec- trodes (0.2 mm diameter) were implanted stereotaxically9 into the following struc- tures: 11. caudatus (CAUD), n. ventralis postero-lateralis (primary relay nucleus) of the thalamus (VPL), the midbrain reticular formation (RF), n. centrum medi- anum (CM), n. amygdalae (AMYG) and formatio hippocampi (HIPP). Stainless steel screws were imbedded in the skull over frontal and parietal cortices. Leads from all electrodes were soldered to miniature Winchester sockets which were secured to the skull with acrylic resin. Two weeks after implantation, the cats were taken to the laboratory for condi- tioning and control tracings. In the following week, isoflurane vapourized through a copper kettle was administered by mask, using a total of 1 L/rain flow of equal parts of air and oxygen in a semiclosed system.
    [Show full text]
  • De Fármacos Antimaláricos
    Facultad de Química-Farmacia Centro de Bioactivos Químicos TOMOCOMD-CARDD: Un Novedoso Enfoque para el Diseño ‘Racional In- Silico’ de Fármacos Antimaláricos Tesis presentada en opción al grado de Licenciado en Ciencias Farmacéuticas. Autor: Carlos Ricardo Romero Zaldivar Tutores: Prof. Inst., Lic. Yovani Marrero Ponce, M.Sc. Prof. Asist., Lic. Maité Iyarreta Veitía, Ph.D. Santa Clara 2004 RESUMEN Nuevos descriptores moleculares útiles para el diseño “racional in silico” de fármacos han sido aplicados a la modelación de la actividad antimalárica. El cálculo de los nuevos índices moleculares fue implementado en el programa TOMOCOMD-CARDD (TOpological MOlecular COMputer Design-Computed Aided ‘Rational’ Drug Design). Los índices cuadráticos y lineales (estocásticos y no estocásticos) fueron usados junto con el análisis discriminante lineal (ADL) para desarrollar modelos QSAR-ADL que permitan la correcta predicción de la actividad antimalárica. Los modelos obtenidos describen adecuadamente la actividad biológica estudiada y en todos los casos clasifican correctamente más del 90.00% de los compuestos en la serie de entrenamiento. En orden de acceder a la robustez y al poder predictivo de los modelos encontrados, procedimientos de validación cruzada interna y externa fueron utilizados. Estas aproximaciones permiten obtener una adecuada explicación de la actividad antimalárica basado en rasgos estructurales evidenciando el rol preponderante de los enlaces de hidrógenos, la presencia de heteroátomos y de las propiedades relacionadas con el tamaño molecular en las interacciones con los sitios dianas antimaláricos. Posteriormente, los modelos desarrollados fueron usados en la simulación de una búsqueda virtual de inhibidores de la farnesil-transferasa (H-Ras) con actividad antimalárica; 84.61% de los inhibidores de la H-Ras usados en esta búsqueda virtual fueron correctamente clasificados por las modelos QSAR-ADL, indicando la habilidad del método TOMOCOMD-CARDD para el descubrimiento de nuevos compuestos líderes con nuevos mecanismos de acción.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Clinical Assessment of an Ipsilateral Cervical Spinal Nerve Block for Prosthetic Laryngoplasty in Anesthetized Horses
    ORIGINAL RESEARCH published: 02 June 2020 doi: 10.3389/fvets.2020.00284 Clinical Assessment of an Ipsilateral Cervical Spinal Nerve Block for Prosthetic Laryngoplasty in Anesthetized Horses Tate B. Morris 1*, Jonathan M. Lumsden 2, Colin I. Dunlop 2, Victoria Locke 2, Sophia Sommerauer 3 and Samuel D. A. Hurcombe 1 1 Department of Clinical Studies, New Bolton Center, University of Pennsylvania, Kennett Square, PA, United States, 2 Randwick Equine Centre, Randwick, NSW, Australia, 3 Department for Companion Animals and Horses, Equine Clinic, University of Veterinary Medicine Vienna, Vienna, Austria The nociceptive blockade of locoregional anesthesia prior to surgical stimulation can decrease anesthetic agent requirement and thereby potential dose-dependent side effects. The use of an ipsilateral second and third cervical spinal nerve locoregional anesthetic block for prosthetic laryngoplasty in the anesthetized horses has yet to be Edited by: described. Anesthetic records of 20 horses receiving locoregional anesthesia prior to Tamas D. Ambrisko, laryngoplasty were reviewed and compared to 20 horses of a similar patient cohort University of Illinois at Urbana-Champaign, United States not receiving locoregional anesthesia. Non-blocked horses were 11 times more likely Reviewed by: to require adjunct anesthetic treatment during surgical stimulation (P = 0.03) and Luis Campoy, were 7.4 times more likely to receive partial intravenous anesthesia in addition to Cornell University, United States Graeme Michael Doodnaught, inhalant anesthesia (P = 0.01). No horse in the blocked group received additional University of Illinois at sedation/analgesia compared to the majority of non-blocked horses (75%) based on Urbana-Champaign, United States the anesthetist’s perception of anesthetic quality and early recovery movement.
    [Show full text]
  • (Columba Livia) Using an Electrical Stimulus
    Article The Determination of the Minimum Anaesthetic Concentration of Halothane in the Rock Dove (Columba livia) Using an Electrical Stimulus Heidi S. Lehmann 1,* , Ngaio J. Beausoleil 1 , Kavitha Kongara 1, Preet M. Singh 1 , John Paul Chambers 1, Gabrielle C. Musk 2 and Craig Johnson 1 1 Animal Welfare Science and Bioethics Centre, School of Veterinary Science, College of Sciences, Massey University, Palmerston North 4472, New Zealand; [email protected] (N.J.B.); [email protected] (K.K.); [email protected] (P.M.S.); [email protected] (J.P.C.); [email protected] (C.J.) 2 Animal Care Services, University of Western Australia, Perth 6907, Australia; [email protected] * Correspondence: [email protected] Simple Summary: An ethical way to examine nociception in animals is to do so when they are anaesthetised. Nociception is the process by which the nervous system perceives a noxious stimulus, and in the conscious animal, this could result in pain. This nociceptive process can still be active in anaesthetised animals, and the resulting electrical activity in the brain can be measured by electroencephalography (EEG). By using this technique, it is possible to quantify the nociceptive response of an animal. To allow comparisons between animals and studies using this model, a method of standardising anaesthetic concentration is required for each species examined. The volatile agent halothane has been used successfully for nociception assessment in both mammals and birds. For volatile anaesthetics, the standardised level is known as the minimum anaesthetic concentration Citation: Lehmann, H.S.; Beausoleil, (MAC).
    [Show full text]